J. William Harbour

Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma

Retrieved on: 
Wednesday, January 12, 2022

DecisionDx-UMSeq is Castles 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma.

Key Points: 
  • DecisionDx-UMSeq is Castles 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma.
  • DecisionDx-UM is the standard of care in the management of newly diagnosed UM in the majority of ocular oncology practices in the United States.
  • The study titled, Analytical validation and performance of a 7-gene next-generation sequencing panel in uveal melanoma, was recently published in the peer-reviewed journal Ocular Oncology and Pathology.
  • Elevated expression of PRAME has been associated with an increased risk of metastasis in patients with uveal melanoma.

Castle Biosciences Collaborates with the Melanoma Research Foundation

Retrieved on: 
Monday, August 2, 2021

Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced its continued collaboration with the Melanoma Research Foundation (MRF), a non-profit organization leading the melanoma community to transform melanoma from one of the deadliest cancers to one of the most treatable through research, education and advocacy.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced its continued collaboration with the Melanoma Research Foundation (MRF), a non-profit organization leading the melanoma community to transform melanoma from one of the deadliest cancers to one of the most treatable through research, education and advocacy.
  • So, we are proud to further our collaboration with the Melanoma Research Foundation.
  • The Melanoma Research Foundation (MRF) is the largest independent organization devoted to melanoma.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005068/en/

Melanoma Research Foundation Launches Historic Patient-Reported Ocular Melanoma Registry

Retrieved on: 
Monday, May 10, 2021

b'WASHINGTON, May 10, 2021 /PRNewswire-PRWeb/ --The Melanoma Research Foundation \'s (MRF) CURE OM initiative today announces the launch of the Virtual Information System to Improve Outcomes and Networks (VISION) Registry , a first of its kind patient-reported, patient-driven ocular melanoma (OM) registry.

Key Points: 
  • b'WASHINGTON, May 10, 2021 /PRNewswire-PRWeb/ --The Melanoma Research Foundation \'s (MRF) CURE OM initiative today announces the launch of the Virtual Information System to Improve Outcomes and Networks (VISION) Registry , a first of its kind patient-reported, patient-driven ocular melanoma (OM) registry.
  • A patient registry is a critical tool to advance medical research, especially for a rare disease where data collection and research collaboration have been historically challenging.
  • The CURE Ocular Melanoma (CURE OM) initiative was founded in 2011 to increase awareness, education and research funding for ocular melanoma.
  • Follow CURE OM on Facebook and Twitter .\nCreated by the Melanoma Research Foundation\'s CURE OM initiative, the Virtual Information System to Improve Outcomes and Networks (VISION) Registry is a first-of-its-kind patient reported, patient powered registry for ocular melanoma patients, caregivers, researchers and physicians.

Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference

Retrieved on: 
Wednesday, January 20, 2021

The virtual poster is entitled, Performance of a 35-gene expression profile test in suspicious pigmented lesions of the head and neck.

Key Points: 
  • The virtual poster is entitled, Performance of a 35-gene expression profile test in suspicious pigmented lesions of the head and neck.
  • We welcome the use of a gene expression profile test to help refine melanoma diagnoses of cases of indeterminate status.
  • DecisionDx DiffDx-Melanoma was used to independently assess 105 lesions located on the head and neck in adults age 18 and up.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq and are trademarks of Castle Biosciences, Inc.

Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma

Retrieved on: 
Friday, December 4, 2020

We expect that this plan will empower physicians to focus more intensive surveillance on high-risk patients who need it most.

Key Points: 
  • We expect that this plan will empower physicians to focus more intensive surveillance on high-risk patients who need it most.
  • Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need.
  • Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq and are trademarks of Castle Biosciences, Inc.

Aura Biosciences Announces AU-011 Data From Phase 1b/2 Clinical Trial Selected for Late Breaking Presentation at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting

Retrieved on: 
Tuesday, November 10, 2020

The abstract details results from the ongoing intravitreal administration Phase 1b/2 clinical study and suprachoroidal administration Phase 2 clinical study evaluating AU-011 in patients with choroidal melanoma.

Key Points: 
  • The abstract details results from the ongoing intravitreal administration Phase 1b/2 clinical study and suprachoroidal administration Phase 2 clinical study evaluating AU-011 in patients with choroidal melanoma.
  • This late-breaking presentation will be given by Carol L. Shields, M.D., Director, Ocular Oncology Service at Wills Eye Hospital, and Professor of Ophthalmology at Thomas Jefferson University.
  • Details for the AAO 2020 presentations are as follows:
    Date and time: Available on demand Nov 14-15, 2020
    Choroidal melanoma is a rare and life-threatening type of eye cancer.
  • It is the most common primary intraocular cancer in adults and develops in the uveal tract of the eye.

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

Retrieved on: 
Monday, November 2, 2020

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that DecisionDx DiffDx-Melanoma is now commercially available.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that DecisionDx DiffDx-Melanoma is now commercially available.
  • DecisionDx DiffDx-Melanoma is designed to provide diagnostic clarity for dermatopathologists and help dermatologists deliver more informed patient management plans.
  • Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq and are trademarks of Castle Biosciences, Inc.

Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma

Retrieved on: 
Thursday, October 8, 2020

Details on the LCD and the billing and coding article are posted to the Medicare Coverage Database on the Centers for Medicare and Medicaid Services (CMS) website.

Key Points: 
  • Details on the LCD and the billing and coding article are posted to the Medicare Coverage Database on the Centers for Medicare and Medicaid Services (CMS) website.
  • We are pleased to have received positive expanded coverage for our DecisionDx-Melanoma test for patients diagnosed with cutaneous melanoma, said Derek Maetzold, president and chief executive officer of Castle Biosciences.
  • This coverage decision provides greater access to our test for people with melanoma, as it allows additional Medicare beneficiaries to incorporate DecisionDx-Melanoma into their management plans.
  • The Company currently offers tests for patients with cutaneous melanoma (DecisionDx-Melanoma, DecisionDx-CMSeq; www.SkinMelanoma.com ), cutaneous squamous cell carcinoma (DecisionDx-SCC, www.mySCCskincancer.com ) and uveal melanoma (DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq; www.MyUvealMelanoma.com ).

Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma

Retrieved on: 
Wednesday, July 15, 2020

The article titled, Gene expression profiling in uveal melanoma: five-year prospective outcomes and meta-analysis, was published in the peer-reviewed journal Ocular Oncology and Pathology.

Key Points: 
  • The article titled, Gene expression profiling in uveal melanoma: five-year prospective outcomes and meta-analysis, was published in the peer-reviewed journal Ocular Oncology and Pathology.
  • UM patients face up to a 50% risk of metastasis, despite successful control of the primary tumor.
  • The multicenter CLEAR Registry Study (Clinical Application of DecisionDx-UM Gene Expression Assay Results) was designed to prospectively evaluate management plans and five-year clinical outcomes for UM patients tested with DecisionDx-UM as part of their clinical care.
  • It is estimated that nearly 8 in 10 patients diagnosed with uveal melanoma in the U.S. receive the DecisionDx-UM test as part of their diagnostic workup.

Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic

Retrieved on: 
Friday, March 27, 2020

The Collaborative Ocular Oncology Group (COOG) represents most major ocular oncology centers in North America who manage patients with uveal melanoma and other ocular tumors.

Key Points: 
  • The Collaborative Ocular Oncology Group (COOG) represents most major ocular oncology centers in North America who manage patients with uveal melanoma and other ocular tumors.
  • Currently, most ocular oncology experts continue to promptly see new patients with eye cancers, such as uveal melanoma, retinoblastoma, intraocular metastasis and vitreoretinal lymphoma.
  • Summary results are attached, and detailed results are available on the Castle Biosciences DecisionDx-UM page: https://castlebiosciences.com/products/decisiondx-um/ .
  • The attached results were prepared by the COOG, and Castle Biosciences makes no representation or warranty as to their accuracy or completeness.